These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
158 related articles for article (PubMed ID: 38976093)
1. A cellular senescence-related signature for predicting prognosis, immunotherapy response, and candidate drugs in patients treated with transarterial chemoembolization (TACE). He N; Zhao W; Tian W; Wu Y; Xu J; Lu Y; Chen X; Zhao H Discov Oncol; 2024 Jul; 15(1):271. PubMed ID: 38976093 [TBL] [Abstract][Full Text] [Related]
2. A cellular senescence-related classifier based on a tumorigenesis- and immune infiltration-guided strategy can predict prognosis, immunotherapy response, and candidate drugs in hepatocellular carcinoma. Luo Y; Liu H; Fu H; Ding GS; Teng F Front Immunol; 2022; 13():974377. PubMed ID: 36458010 [TBL] [Abstract][Full Text] [Related]
3. A Three-Gene Signature for Predicting the Prognosis of Patients Treated with Transarterial Chemoembolization (TACE) and Identification of PD-184352 as a Potential Drug to Reverse Nonresponse to TACE. Xia Z; Zhao W; Liu J; Zhang J; Pan J; Chen K; Wang L; Zhao H; Chen X J Oncol; 2022; 2022():2704862. PubMed ID: 36213835 [TBL] [Abstract][Full Text] [Related]
4. Overweight/obesity-related transcriptomic signature as a correlate of clinical outcome, immune microenvironment, and treatment response in hepatocellular carcinoma. Feng NN; Du XY; Zhang YS; Jiao ZK; Wu XH; Yang BM Front Endocrinol (Lausanne); 2022; 13():1061091. PubMed ID: 36714595 [TBL] [Abstract][Full Text] [Related]
5. An Oxidative Stress-Related Prognostic Signature Predicts Treatment Response and Outcomes for Hepatocellular Carcinoma After Transarterial Chemoembolization. Ma H; Yu T; Li ZC; Zhang L; Chen RX; Ren ZG J Hepatocell Carcinoma; 2024; 11():1569-1580. PubMed ID: 39156675 [TBL] [Abstract][Full Text] [Related]
6. Immune-related gene signature to predict TACE refractoriness in patients with hepatocellular carcinoma based on artificial neural network. Xu Q; Wang C; Yin G Front Genet; 2022; 13():993509. PubMed ID: 36685822 [No Abstract] [Full Text] [Related]
7. Development and Validation of TACE Refractoriness-Related Diagnostic and Prognostic Scores and Characterization of Tumor Microenvironment Infiltration in Hepatocellular Carcinoma. He Q; Yang J; Jin Y Front Immunol; 2022; 13():869993. PubMed ID: 35493518 [TBL] [Abstract][Full Text] [Related]
8. Mitochondrial-Related Transcriptome Feature Correlates with Prognosis, Vascular Invasion, Tumor Microenvironment, and Treatment Response in Hepatocellular Carcinoma. Wang Y; Song F; Zhang X; Yang C Oxid Med Cell Longev; 2022; 2022():1592905. PubMed ID: 35535359 [TBL] [Abstract][Full Text] [Related]
9. Identification and validation of a novel senescence-related biomarker for thyroid cancer to predict the prognosis and immunotherapy. Hong K; Cen K; Chen Q; Dai Y; Mai Y; Guo Y Front Immunol; 2023; 14():1128390. PubMed ID: 36761753 [TBL] [Abstract][Full Text] [Related]
10. Identification of PANoptosis-Based Prognostic Signature for Predicting Efficacy of Immunotherapy and Chemotherapy in Hepatocellular Carcinoma. Xiong X; Song Q; Jing M; Yan W Genet Res (Camb); 2023; 2023():6879022. PubMed ID: 37313428 [TBL] [Abstract][Full Text] [Related]
11. A novel prognostic signature based on immunogenic cell death score predicts outcomes and response to transcatheter arterial chemoembolization and immunotherapy in hepatocellular carcinoma. Zhang Y; Yang J; Xie S; Chen H; Zhong J; Lin X; Yu Z; Xia J J Cancer Res Clin Oncol; 2023 Oct; 149(13):11411-11429. PubMed ID: 37382674 [TBL] [Abstract][Full Text] [Related]
12. Identification of cell senescence molecular subtypes in prediction of the prognosis and immunotherapy of hepatitis B virus-related hepatocellular carcinoma. Yu X; Chen P; Yi W; Ruan W; Xiong X Front Immunol; 2022; 13():1029872. PubMed ID: 36275676 [TBL] [Abstract][Full Text] [Related]
13. A novel signature incorporating lipid metabolism- and immune-related genes to predict the prognosis and immune landscape in hepatocellular carcinoma. Yang T; Luo Y; Liu J; Liu F; Ma Z; Liu G; Li H; Wen J; Chen C; Zeng X Front Oncol; 2023; 13():1182434. PubMed ID: 37346073 [TBL] [Abstract][Full Text] [Related]
14. A Novel Ferroptosis-Related Signature for Prediction of Prognosis, Immune Profiles and Drug Sensitivity in Hepatocellular Carcinoma Patients. Zhao C; Zhang Z; Tao J Curr Oncol; 2022 Sep; 29(10):6992-7011. PubMed ID: 36290827 [TBL] [Abstract][Full Text] [Related]
15. Basement membrane-related regulators for prediction of prognoses and responses to diverse therapies in hepatocellular carcinoma. Ding R; Zhao C; Jing Y; Chen R; Meng Q BMC Med Genomics; 2023 Apr; 16(1):81. PubMed ID: 37081465 [TBL] [Abstract][Full Text] [Related]
16. Identification of senescence-associated long non-coding RNAs to predict prognosis and immune microenvironment in patients with hepatocellular carcinoma. Gao C; Zhou G; Cheng M; Feng L; Cao P; Zhou G Front Genet; 2022; 13():956094. PubMed ID: 36330438 [No Abstract] [Full Text] [Related]
17. Construction and validation of an angiogenesis-related scoring model to predict prognosis, tumor immune microenvironment and therapeutic response in hepatocellular carcinoma. Tang B; Zhang X; Yang X; Wang W; Li R; Liu Y Front Immunol; 2022; 13():1013248. PubMed ID: 36466855 [TBL] [Abstract][Full Text] [Related]
18. Identification and Validation of a Novel Tumor Microenvironment-Related Prognostic Signature of Patients With Hepatocellular Carcinoma. Li R; Zhao W; Liang R; Jin C; Xiong H Front Mol Biosci; 2022; 9():917839. PubMed ID: 35847972 [No Abstract] [Full Text] [Related]
19. Cellular senescence affects energy metabolism, immune infiltration and immunotherapeutic response in hepatocellular carcinoma. Gao B; Wang Y; Lu S Sci Rep; 2023 Jan; 13(1):1137. PubMed ID: 36670201 [TBL] [Abstract][Full Text] [Related]
20. Comprehensive analysis of cellular senescence-related genes in the prognosis, tumor microenvironment, and immunotherapy/chemotherapy of clear cell renal cell carcinoma. Lu C; Wang Y; Nie L; Chen L; Li M; Qing H; Li S; Wu S; Wang Z Front Immunol; 2022; 13():934243. PubMed ID: 36189255 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]